Back | Next |
home / stock / okyo / okyo message board
Subject | By | Source | When |
---|---|---|---|
$OKYO under $2 https://investorshub.advfn.com/uimage/uploads/2023/10/2/ladfe | Monksdream | investorshub | 10/02/2023 7:20:01 AM |
$OKYO good read | Ryguy008 | investorshub | 10/02/2023 6:58:56 AM |
$OKYO Price gaining | mfayman | investorshub | 10/02/2023 6:11:30 AM |
$OKYO bears are running | Count Crypto | investorshub | 10/02/2023 2:51:53 AM |
$OKYO Long and strong lets hope im right | Pisd | investorshub | 10/01/2023 11:58:59 PM |
$OKYO The now | mfayman | investorshub | 10/01/2023 11:49:30 PM |
Wanna see that volume pour in tomorrow and | mfayman | investorshub | 10/01/2023 11:41:06 PM |
short data if anyone is interested | glenn1919 | investorshub | 10/01/2023 4:08:32 PM |
$OKYO Time for this to show some returns | Count Crypto | investorshub | 10/01/2023 4:03:27 PM |
$OKYO we got news | glenn1919 | investorshub | 10/01/2023 3:01:41 PM |
$OKYO Price gaining last up | Pisd | investorshub | 10/01/2023 2:46:03 PM |
The gaining | Count Crypto | investorshub | 10/01/2023 12:46:08 PM |
$OKYO Price gaining | Sirpeter | investorshub | 10/01/2023 11:31:24 AM |
Thoughts on where this is headed? | mfayman | investorshub | 10/01/2023 11:09:21 AM |
bears and bulls | Count Crypto | investorshub | 10/01/2023 10:40:03 AM |
$OKYO Good read | Pisd | investorshub | 10/01/2023 9:44:40 AM |
just the news we needed | glenn1919 | investorshub | 10/01/2023 9:28:30 AM |
$OKYO The gaining | Count Crypto | investorshub | 10/01/2023 8:49:45 AM |
bulls and bears | Count Crypto | investorshub | 10/01/2023 8:20:31 AM |
$OKYO The gaining up | Sirpeter | investorshub | 10/01/2023 2:52:56 AM |
News, Short Squeeze, Breakout and More Instantly...
--News Direct-- OKYO Pharma Ltd CEO Gary Jacobs joined Steve Darling from Proactive to share additional key findings from the Phase 2 clinical trial evaluating the safety and efficacy of OK-101 (0.05%) ophthalmic solution in patients with dry eye disease (DED). This trial involved 240 pat...
LONDON and NEW YORK, May 08, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflammatory dry eye disease (DED), a multi-billion-dollar market, and anterior ocular segment diseases ...
LONDON and NEW YORK, April 30, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflammatory dry eye disease (DED), a multi-billion-dollar market, and anterior ocular segment disease...